SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
1-Year Return
71.55%
This Quarter Return
+6.38%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$405M
AUM Growth
+$48.5M
(+14%)
Cap. Flow
+$85.6M
Cap. Flow
% of AUM
21.14%
Top 10 Holdings %
Top 10 Hldgs %
49.16%
Holding
86
New
12
Increased
27
Reduced
11
Closed
19
Top Buys
| 1 |
Nuvalent
NUVL
|
$23.4M |
| 2 |
Erasca
ERAS
|
$17.9M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$10.8M |
| 4 |
UroGen Pharma
URGN
|
$9.96M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$8.75M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$7.89M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$5.98M |
| 3 |
Perspective Therapeutics
CATX
|
$5.49M |
| 4 |
Praxis Precision Medicines
PRAX
|
$5.1M |
| 5 |
Solid Biosciences
SLDB
|
$4.83M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBOT
26
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$789M
| $5.11M | 1.21% |
500,000
| – | – |
|
27
Mersana Therapeutics
MRSN
$34.4M
| $5.03M | 1.19% |
100,023
-18,729
| -16% | -$941K |
|
28
Gossamer Bio
GOSS
$562M
| $4.95M | 1.17% |
5,500,000
-630,268
| -10% | -$568K |
|
29
TELA Bio
TELA
$62.2M
| $4.7M | 1.11% |
1,000,000
+223,149
| +29% | +$1.05M |
|
30
Disc Medicine
IRON
$2.09B
| $4.56M | 1.08% |
+101,187
| New | +$4.56M |
|
31
Biogen
BIIB
$20.3B
| $4.49M | 1.06% |
19,365
| – | – |
|
|
VRNA
32
Verona Pharma
VRNA
$9.18B
| $4.4M | 1.04% |
304,633
+167,919
| +123% | +$2.43M |
|
33
Geron
GERN
$880M
| $4.24M | 1% |
999,270
+749,270
| +300% | +$3.18M |
|
34
Biohaven
BHVN
$1.7B
| $3.47M | 0.82% |
+100,000
| New | +$3.47M |
|
|
LBPH
35
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $3.32M | 0.78% |
+122,849
| New | +$3.32M |
|
|
36
Praxis Precision Medicines
PRAX
$958M
| $2.78M | 0.66% |
67,296
-123,260
| -65% | -$5.1M |
|
37
Structure Therapeutics
GPCR
$1.12B
| $2.77M | 0.65% |
70,516
+60,516
| +605% | +$2.38M |
|
38
Biodesix
BDSX
$67.4M
| $2.77M | 0.65% |
+1,808,959
| New | +$2.77M |
|
39
Mirum Pharmaceuticals
MIRM
$3.74B
| $2.71M | 0.64% |
79,194
| – | – |
|
|
40
Solid Biosciences
SLDB
$428M
| $2.68M | 0.63% |
472,995
-852,070
| -64% | -$4.83M |
|
|
41
Perspective Therapeutics
CATX
$255M
| $2.59M | 0.61% |
260,009
-550,802
| -68% | -$5.49M |
|
42
Cerus
CERS
$253M
| $2.58M | 0.61% |
1,465,744
| – | – |
|
43
Compugen
CGEN
$130M
| $2.52M | 0.6% |
1,501,113
+501,113
| +50% | +$842K |
|
44
Trevi Therapeutics
TRVI
$869M
| $2.52M | 0.59% |
844,235
| – | – |
|
45
Kodiak Sciences
KOD
$450M
| $2.5M | 0.59% |
1,062,062
-176,760
| -14% | -$415K |
|
46
Jasper Therapeutics
JSPR
$43.6M
| $2.49M | 0.59% |
109,892
| – | – |
|
47
enGene Holdings
ENGN
$247M
| $2.49M | 0.59% |
+263,841
| New | +$2.49M |
|
48
Wave Life Sciences
WVE
$1.28B
| $2.47M | 0.58% |
495,471
| – | – |
|
49
Fulcrum Therapeutics
FULC
$367M
| $2.47M | 0.58% |
398,436
| – | – |
|
50
Evogene
EVGN
$10.6M
| $2M | 0.47% |
307,974
-576
| -0.2% | -$3.75K |
|